ReadingResearchRadarInvestment framework
Sign in / Sign up
← Back to reading
NewsMaterial2 min readDisconfirmAI Editorial

DeepMind Spinout Isomorphic Labs Raises $5B Series C to Advance AI Drugs to Clinical Trials

Isomorphic Labs has closed a $5 billion Series C round led by Greenoaks and Sequoia Capital to move AI-designed drug candidates into clinical testing.

2026-11-17 22:50 GMT+8

Isomorphic Labs, an AI drug-discovery platform spun out of Google’s DeepMind in 2021, has announced the completion of a $5 billion Series C funding round. The investment was co-led by Greenoaks and Sequoia Capital, with participation from new investor Andreessen Horowitz and existing backers including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.

The new capital will be used to continue developing the company's AI drug-design engine and to expand into more types of medicine. Isomorphic Labs utilizes a suite of simulation AI models to explore various areas of chemistry to assist in drug design. Building on DeepMind’s breakthrough AlphaFold protein-folding AI model, the company stated that its program has yielded “positive preclinical results” in oncology and immunology. It has also struck deals with pharmaceutical giants such as Eli Lilly, Novartis, and Johnson & Johnson.

This raise follows a $2.1 billion Series B round completed in May. Notably, this is Isomorphic Labs' first fundraise since founder and CEO Demis Hassabis left his position as head of DeepMind to focus on drug discovery, moving into a chairman role at the lab instead. Hassabis and former DeepMind director John Jumper won the Nobel Prize in Chemistry for their work on AlphaFold, a system capable of predicting the 3D structure of proteins using only their genetic sequence.

Isomorphic Labs did not disclose its new valuation. Bloomberg reported earlier this month that the lab was seeking to raise funds at a valuation of approximately $50 billion.

Sources

Sign in / Sign up
ReadingResearchRadarInvestment framework
techcrunch.comTechCrunch↗
Continue researching →